CA3149467A1 - Ophthalmic formulations of methotrexate - Google Patents
Ophthalmic formulations of methotrexate Download PDFInfo
- Publication number
- CA3149467A1 CA3149467A1 CA3149467A CA3149467A CA3149467A1 CA 3149467 A1 CA3149467 A1 CA 3149467A1 CA 3149467 A CA3149467 A CA 3149467A CA 3149467 A CA3149467 A CA 3149467A CA 3149467 A1 CA3149467 A1 CA 3149467A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- mtx
- sorbitan
- administered
- tween
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900060P | 2019-09-13 | 2019-09-13 | |
| US62/900,060 | 2019-09-13 | ||
| US202063044288P | 2020-06-25 | 2020-06-25 | |
| US63/044,288 | 2020-06-25 | ||
| PCT/US2020/050565 WO2021051003A1 (en) | 2019-09-13 | 2020-09-11 | Ophthalmic formulations of methotrexate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3149467A1 true CA3149467A1 (en) | 2021-03-18 |
Family
ID=74866765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3149467A Pending CA3149467A1 (en) | 2019-09-13 | 2020-09-11 | Ophthalmic formulations of methotrexate |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US12616699B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4028015A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7682512B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220062617A (cg-RX-API-DMAC10.html) |
| CN (1) | CN114423432A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020344685A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3149467A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL291228A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021051003A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021051003A1 (en) | 2019-09-13 | 2021-03-18 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024129979A1 (en) * | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253243A1 (en) | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20050101605A1 (en) | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| WO2005046746A2 (en) | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| MX2007003968A (es) | 2004-10-01 | 2008-03-04 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| JP2008539276A (ja) | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
| US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| US20110200662A1 (en) | 2008-10-22 | 2011-08-18 | Arnold Glazier | Method For The Treatment Of Proliferative Disorders Of The Eye |
| CN105362221A (zh) | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| GB201200192D0 (en) * | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| US20140105956A1 (en) | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| CA2991921C (en) | 2014-07-30 | 2023-08-08 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| GB201522441D0 (en) * | 2015-12-18 | 2016-02-03 | Midatech Pharma Wales Ltd | Sustained release cyclosporine-loaded microparticles |
| WO2018201146A1 (en) | 2017-04-28 | 2018-11-01 | Case Western Reserve University | Compounds and methods of treating retinal degeneration |
| CA3092828A1 (en) | 2018-03-01 | 2019-09-06 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress |
| WO2021051003A1 (en) | 2019-09-13 | 2021-03-18 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| US12678440B2 (en) | 2020-02-26 | 2026-07-14 | Case Western Reserve University | Compositions and methods for treating misfolded protein ocular disorders |
| WO2024129979A1 (en) | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
-
2020
- 2020-09-11 WO PCT/US2020/050565 patent/WO2021051003A1/en not_active Ceased
- 2020-09-11 EP EP20863798.3A patent/EP4028015A4/en active Pending
- 2020-09-11 CA CA3149467A patent/CA3149467A1/en active Pending
- 2020-09-11 US US17/753,721 patent/US12616699B2/en active Active
- 2020-09-11 KR KR1020227012402A patent/KR20220062617A/ko not_active Ceased
- 2020-09-11 JP JP2022515885A patent/JP7682512B2/ja active Active
- 2020-09-11 CN CN202080063801.6A patent/CN114423432A/zh active Pending
- 2020-09-11 AU AU2020344685A patent/AU2020344685A1/en not_active Abandoned
-
2022
- 2022-03-09 IL IL291228A patent/IL291228A/en unknown
- 2022-09-15 US US17/932,426 patent/US12005060B2/en active Active
- 2022-09-15 US US17/932,453 patent/US12005061B2/en active Active
-
2026
- 2026-04-09 US US19/643,612 patent/US20260224578A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021051003A1 (en) | 2021-03-18 |
| US20230018197A1 (en) | 2023-01-19 |
| US20230017743A1 (en) | 2023-01-19 |
| US12616699B2 (en) | 2026-05-05 |
| KR20220062617A (ko) | 2022-05-17 |
| US12005060B2 (en) | 2024-06-11 |
| US20260224578A1 (en) | 2026-08-06 |
| CN114423432A (zh) | 2022-04-29 |
| EP4028015A4 (en) | 2023-11-15 |
| US20220370460A1 (en) | 2022-11-24 |
| US12005061B2 (en) | 2024-06-11 |
| EP4028015A1 (en) | 2022-07-20 |
| JP7682512B2 (ja) | 2025-05-26 |
| IL291228A (en) | 2022-05-01 |
| AU2020344685A1 (en) | 2022-04-14 |
| JP2022548226A (ja) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12005060B2 (en) | Ophthalmic formulations of methotrexate | |
| AU2017200608B2 (en) | Liquid pharmaceutical composition for the treatment of a posterior eye disease | |
| JP2019518730A (ja) | 眼の炎症性障害および疾患の組合せ処置 | |
| US20080125406A1 (en) | Method for Treating Primary and Secondary Forms of Glaucoma | |
| KR20080059280A (ko) | 녹내장의 원발성 및 ２차 형태의 치료 방법 | |
| JP2017531045A (ja) | 眼科用液剤 | |
| JP7080268B2 (ja) | 一酸化窒素放出プロスタミドを含有する眼科用組成物 | |
| JP2018500295A (ja) | 術後眼炎症状態を阻害するための抗炎症性かつ散瞳性前房内溶液 | |
| GR1009419B (el) | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου | |
| US20070043006A1 (en) | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| JP2013129604A (ja) | 緑内障治療薬を含有する徐放性フィルム製剤 | |
| Gaballa et al. | Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs): Ocular Pharmacology, Pharmaceutical Innovations, and Drug Delivery Perspectives | |
| AU2024366119A1 (en) | Compositions and methods for treating neural degeneration in glaucoma and related conditions | |
| CN101365456A (zh) | 治疗原发性和继发性形式的青光眼的方法 | |
| HK1235304B (en) | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240910 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240910 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240910 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241003 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241203 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250905 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250917 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260128 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260128 |